Axogen to buy BioCircuit for $200 million, prices $208.7 million stock offering

What happened

Axogen, Inc. (Nasdaq: AXGN), a Minnesota corporation based in Alachua, Florida, disclosed two connected transactions in a Form 8-K filed September 10, 2026. Axogen makes medical devices used to repair damaged peripheral nerves.

First, on September 9, 2026, Axogen entered an Agreement and Plan of Merger to acquire BioCircuit Technologies, Inc., a Georgia corporation. Under the structure described in the filing, Axogen's wholly owned subsidiary, Omega Merger Sub, Inc., will merge into BioCircuit, and BioCircuit will survive as a wholly owned Axogen subsidiary. The base purchase price is $200.0 million in cash, subject to adjustments for cash, debt, transaction expenses and net working capital. At closing, $1.0 million will be held back for post-closing purchase price adjustments.

Second, on September 10, 2026, Axogen signed an underwriting agreement with BofA Securities, Jefferies and Wells Fargo Securities as representatives of the underwriters, to sell 4,910,000 shares of common stock at a public offering price of $42.50 per share. Underwriters pay $39.95 per share, a discount of $2.55. Axogen granted a 30-day option for up to 736,500 additional shares.

The filing states Axogen intends to use the offering's net proceeds to finance the merger. The offering is expected to close September 11, 2026. The merger is expected to close in the fourth quarter of 2026 and, per the filing, is not expected to require regulatory approvals.

What Axogen is buying

BioCircuit's core business, as described in the filing, is developing and commercializing two products, NerveTape and ConformaWrap, for repair of peripheral nerve discontinuities — gaps where a nerve has been severed or damaged. That places BioCircuit in roughly the same clinical territory as Axogen's own nerve-repair products, though the filing does not say that directly.

Before closing, BioCircuit will spin out an unrelated electronics business to its own stockholders, so Axogen is not acquiring that unit. All of BioCircuit's outstanding convertible promissory notes must be converted into BioCircuit common stock before closing.

Two closing conditions are named in the filing: consent under an inbound intellectual property license agreement, and the spin-out of the electronics research and development business.

What this means

An 8-K is a current report. Public companies file one when something material happens between quarterly reports; it is not an earnings document. The item numbers tell you what is inside. Item 1.01 means the company signed a contract significant enough to matter to investors. Here that is the merger agreement. Item 7.01 is Regulation FD disclosure, the rule that stops a company from selectively telling big investors something small investors don't know; Axogen used it to attach a merger press release and an investor presentation. Item 9.01 lists the exhibits, including the underwriting agreement and a legal opinion on the share issuance.

The acquisition is a cash deal, not a stock deal, which is why the offering exists. Axogen needed $200.0 million in cash plus fees, and its own 8-K says it intends to use the offering proceeds for exactly that. The offering price of $42.50 per share is itself a disclosure: the shares closed at $42.4225 the day of the filing, up 1.37% from the prior close of $41.85, essentially at the offering price.

The gap between what the public pays ($42.50) and what the underwriters pay ($39.95) is the underwriting discount, the fee investment banks earn for buying the shares from the company and reselling them. It runs about 6% of the offering price. Companies usually grant the extra 30-day option — the greenshoe — so underwriters can cover excess demand without destabilizing the aftermarket.

Two details in the merger agreement are worth flagging for what they mean mechanically. Axogen agreed to obtain sufficient funding within 90 days of signing and failing to do so is a breach, but the merger itself is not conditioned on financing — a structure that shifts the funding risk to Axogen rather than BioCircuit. And the agreement has no termination fee, meaning if either side walks away under the permitted termination rights, no breakup payment is owed. Either party can terminate if the deal has not closed by December 31, 2026.

The filing also includes a risk factor stating the merger may not be completed on the anticipated terms or timeline, or at all, and that integration may be difficult, costly or time-consuming. That language is standard in merger filings, but it is the company's own statement, and the filing gives no assurance the deal closes.

What normally happens next: the offering is expected to close September 11, 2026, and the merger is expected to close in the fourth quarter of 2026, pending the consent, note conversions and spin-out listed above. Axogen said it will file the full merger agreement as Exhibit 2.1 to an amendment to this 8-K; the filing does not state when that amendment will be filed.